New drug shows promise for liver cirrhosis fluid retention

NCT ID NCT05249374

Completed Disease control Sponsor: Protgen Ltd Source: ClinicalTrials.gov ↗

First seen Mar 26, 2026 · Last updated Apr 23, 2026 · Updated 2 times

Summary

This early-stage study tested a new medicine called r-HSA in 36 adults with liver cirrhosis and ascites (fluid buildup in the belly). The goal was to check if the drug is safe and how the body processes it. Participants received one of three doses of r-HSA or an active comparison drug. The study is complete, but results are not yet available.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATIC ASCITES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Hebei Petro China Central Hospital

Shijiazhuang, Hebei, 050000, China
Peking Union Medical College Hospital

Beijing, Beijing Municipality, 100000, China
Pingxiang People's Hospital

Pingxiang, Jiangxi, 337000, China
Shenzhen Protgen Co., Ltd.

Shenzhen, Guangdong, 100084, China
Shenzhen Third People's Hospital

Shenzhen, Guangdong, 518000, China
The First Hospital of Changsha

Changsha, Hunan, 410005, China
Yichun People's Hospital

Yichun, Jiangxi, 336000, China
Yiyang Central Hospital

Yiyang, Hunan, 413000, China

Conditions

Explore the condition pages connected to this study.

HEPATIC ASCITES